At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Market Closed 10-16 16:00:00 EDT
3.27
-0.30
-8.40%
盘后3.26
-0.01-0.31%
19:59 EDT
High3.56Low3.21Vol939.08K
Open3.56D1 Closing3.57Amplitude9.80%
Mkt Cap102.32MTradable Cap60.15MTotal Shares31.29M
T/O3.10MT/O Rate5.11%Tradable Shares18.39M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Learn Why The Bull Case For PYC Therapeutics Stock Could Change Following Early Kidney Trial Data
Simply Wall St.  ·  10-17 16:33
Learn Why The Bull Case For PYC Therapeutics Stock Could Change Following Early Kidney Trial Data
Top Executive at Aquestive Therapeutics Makes Notable Stock Move
TIPRANKS  ·  10-17 10:02
Top Executive at Aquestive Therapeutics Makes Notable Stock Move
TScan Therapeutics Announces Board and Governance Changes
TIPRANKS  ·  10-17 05:21
TScan Therapeutics Announces Board and Governance Changes
Tango Therapeutics management to meet with Cantor
TIPRANKS  ·  10-17 04:50
Tango Therapeutics management to meet with Cantor
Maze Therapeutics adjusts equity via warrant exchange
TIPRANKS  ·  10-17 04:34
Maze Therapeutics adjusts equity via warrant exchange
Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says
MT Newswires Live  ·  10-17 00:01
Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says
Knight Therapeutics price target raised to C$12.25 from C$11 at Stifel
TIPRANKS  ·  10-16 22:30
Knight Therapeutics price target raised to C$12.25 from C$11 at Stifel
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
GlobeNewswire  ·  10-16 20:30
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Sarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35
TIPRANKS  ·  10-16 19:58
Sarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
GlobeNewswire  ·  10-16 19:00
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Jefferies Names Spyre Therapeutics a Top Biotech Pick for 2027, With Phase II Data Due on Three IBD Combination Therapies
Deep News  ·  10-16 15:30
Jefferies Names Spyre Therapeutics a Top Biotech Pick for 2027, With Phase II Data Due on Three IBD Combination Therapies
Tango Therapeutics initiated with an Outperform at William Blair
TIPRANKS  ·  10-16 08:50
Tango Therapeutics initiated with an Outperform at William Blair
Hemab Therapeutics Initiated at Overweight by JP Morgan
Dow Jones  ·  10-16 06:40
Hemab Therapeutics Initiated at Overweight by JP Morgan
Ovid Therapeutics Price Target Announced at $5.00/Share by Wolfe Research
Dow Jones  ·  10-16 06:38
Ovid Therapeutics Price Target Announced at $5.00/Share by Wolfe Research
Eterna Therapeutics Updates Investor Presentation and Disclosures
TIPRANKS  ·  10-16 05:48
Eterna Therapeutics Updates Investor Presentation and Disclosures
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
GlobeNewswire  ·  10-16 04:05
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Avalo Therapeutics: Buy Rating Reiterated as Abdakibart’s Differentiated Profile and Upcoming Milestones Support Unchanged $30 Price Target
TIPRANKS  ·  10-15 23:15
Avalo Therapeutics: Buy Rating Reiterated as Abdakibart’s Differentiated Profile and Upcoming Milestones Support Unchanged $30 Price Target
Crispr Therapeutics management to meet with Piper Sandler
TIPRANKS  ·  10-15 21:45
Crispr Therapeutics management to meet with Piper Sandler
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
GlobeNewswire  ·  10-15 21:20
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
Needham & Co Initiates Coverage on CAMP4 Therapeutics With Buy Rating, $8 Price Target
MT Newswires Live  ·  10-15 19:41
Needham & Co Initiates Coverage on CAMP4 Therapeutics With Buy Rating, $8 Price Target

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--